Mounjaro Sales in the UK: What Rapid Growth Means If You're Considering Treatment

You've heard Mounjaro is everywhere. Here's what the sales picture actually looks like.

Picture this: you search for Mounjaro, and every second result is either a pharmacy offering it privately or a news headline about record prescribing figures. It can feel like everyone is on it. The reality is more nuanced. UK tirzepatide sales have grown steadily since Eli Lilly received the weight-management licence, accelerated after NICE published its appraisal of tirzepatide (TA1026) in December 2024, and then spiked again as NHS phased rollout began expanding eligibility through 2025 and 2026. Private prescribing drove most early volume, because NHS access remains gated behind strict criteria and a phased timetable.

The commercial picture shifted materially in autumn 2025. Lilly's list price increase, from roughly £122 to roughly £330 per four-week pen at the highest dose, meant that overall sales revenue rose even more steeply than unit volumes, as widely reported in August 2025. For patients, that translated into higher private prices across most providers. If you want a closer read of how those figures broke down year by year, Eli Lilly's tirzepatide sales figures for 2024 give useful context before the price change landed.

None of this changes what Mounjaro actually is: a dual GIP and GLP-1 receptor agonist that works on two gut-hormone pathways to reduce appetite and slow gastric emptying. The sales numbers reflect clinical results that impressed regulators and trialists alike, but they also reflect hype, and the two are worth separating before you make any decisions.

What rising Mounjaro sales in the UK have brought with them, including risks you should know about

High demand for any controlled medicine creates pressure points. The most serious one here is counterfeits. As the MHRA's Yellow Card scheme documents, the regulator has seized approximately 20 million doses of illegally traded weight-loss medicines (roughly £45 million street value) and, in October 2025, raided the first illicit UK site producing counterfeit tirzepatide pens. Fake pens have been found to contain insulin rather than tirzepatide, not a theoretical risk.

The quick check anyone can do in under a minute: go to the GPhC pharmacy register, type in the pharmacy's name, and confirm they hold a valid registration. If a seller doesn't appear there, or if they're offering Mounjaro without a prescription from a verified prescriber, that's a clear red flag regardless of how professional their website looks.

The broader pattern is consistent: sellers targeting the gap between high demand and limited NHS access tend to cut corners on clinical oversight, supply chain verification, or both. Booming tirzepatide sales across the UK have made that gap a target for illegitimate operators. A surge in sales figures is only a good-news story when those sales are going through verified, licensed channels.

For anyone researching whether Mounjaro sales have started to slow or plateau, the short answer is that there's no sign of that yet, NHS rollout is still widening, and private demand has remained robust despite the price increase.

NHS versus private: why the sales split matters for how you'd actually access treatment

Most UK Mounjaro sales to date have been private, for one straightforward reason: NHS eligibility has been deliberately phased. NICE's TA1026 recommendation set strict entry criteria, and the NHS England rollout is adding cohorts gradually, with Cohort 2 (BMI 35–39.9 plus four or more qualifying conditions) activating in June 2026. People who meet the criteria may still face a wait, depending on their GP practice's participation and local ICB provision.

Private treatment through a GPhC-registered online pharmacy fills that gap for people who are clinically suitable but either don't meet NHS thresholds or prefer not to wait. The process mirrors what the NHS requires in clinical rigour, even if it doesn't mirror the cost: a prescriber assesses your health history, weight, BMI and relevant conditions, then makes an individual decision. No assessment, no prescription. That's the legal position for a Prescription-Only Medicine, and it's also the right one.

If you're considering buying Mounjaro online through a private pharmacy, the NHS England guidance on weight-management injections is worth reading first, it covers eligibility principles and the wraparound lifestyle support that should accompany any GLP-1 treatment. You can also explore how meal-replacement products like Huel interact with Mounjaro use for practical guidance on what to eat alongside treatment.

Sales growth has also sparked interest in alternatives. Our weight-loss treatment overview covers the full range of licensed options available through nume (including Wegovy) for anyone comparing before committing. Cost is a real consideration; for a frank breakdown of what private treatment prices include and why the cheapest listing isn't the right measure for a prescription medicine, the Mounjaro cost and value explainer covers the ground without spin.